TEVA PHARMACEUTICAL INDUSTRIES LTD. ANNOUNCES FDA APPROVAL OF FLURBIPROFEN AND DILTIAZEM -- Teva's Seventh and Eighth Approvals in 1995 --.

JERUSALEM, Israel, May 31, 1995--(BUSINESS WIRE)--Teva Pharmaceutical Industries Limited (Nasdaq:TEVIY), Israel's largest pharmaceutical company, announced today it has received approval from the Food and Drug Administration to manufacture and market both Flurbiprofen and Diltiazem tablets.

Flurbiprofen is a generic equivalent of Upjohn's nonsteroidal anti-inflammatory Ansaid and Diltiazem is a generic equivalent of Marion Merrell Dow's Cardizem . Although there are several generic equivalents of these products available, the U.S. market for Flurbiprofen is now estimated to be approximately $110 million and the U.S. market for Diltiazem is estimated to be approximately $95 million. The approval for Diltiazem tablets broadens Teva's position in the calcium channel blocker market, in which Teva is currently the sole generic producer of Diltiazem ER, a sustained release formulation of Diltiazem.

These approvals mark Teva's seventh and eighth product approvals this year, following the approval of Miconazole vaginal cream (a generic equivalent of Ortho's Monistat(R), Atenolol tablets (a generic equivalent of Zeneca's Tenormin(R), Metoprolol tablets (a generic equivalent of Geigy's Lopressor(R), Cimetidine tablets (a generic equivalent of SmithKline Beecham's Tagamet(R), Clotrimazole Topical Solution (a generic equivalent to Schering's Lotrimin AF(R) and Nortriptyline (a generic equivalent of Sandoz's Pamelor(R).

Teva Pharmaceutical Industries Limited, Israel's largest pharmaceutical company, develops, manufactures and markets human pharmaceuticals, bulk pharmaceutical chemicals, medical disposables and veterinary products. The largest supplier of such products to Israel's public and private healthcare markets, the Company has manufacturing facilities in Israel, Western Europe and the United States and over 60 percent of its sales are generated outside of Israel.

CONTACT: Dan Suesskind

Chief Financial Officer

Teva Pharmaceutical Industries, Ltd.

(011) 972-2-892-811

OR

Investor Relations Contact:

Donna Stein, APR/Courtney Kraft

Morgen-Walke Associates, Inc.

[phone]

OR

Press Contact:

Brian Maddox

Morgen-Walke Associates, Inc.

[phone]